Stealth BioTherapeutics (NASDAQ:MITO) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate.
Stealth BioTherapeutics Q3 EPS $(0.04), Inline
Stealth BioTherapeutics (NASDAQ:MITO) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate.
Benzinga · 11/14/2019 12:20